A 58-year-old man with a 3-year history of dilated cardiomyopathy (LVEF 28%) and symptomatic heart failure (NYHA Class III) is initiated on standard heart failure therapy. He is already on a beta-blocker and an ACE inhibitor. Which drug should be added next as the evidence-based third pillar of neurohormonal blockade?

Explanation

## Rationale for Spironolactone **Key Point:** Aldosterone antagonists (spironolactone, eplerenone) are the third pillar of neurohormonal blockade in systolic heart failure, after ACE-I/ARB and beta-blockers. **High-Yield:** The RALES trial (1999) demonstrated that spironolactone reduces mortality by 30% in moderate-to-severe systolic HF (LVEF ≤35%), independent of diuretic effect. This landmark study established aldosterone antagonism as a cornerstone therapy. ### Triple Neurohormonal Blockade in Systolic HF | Drug Class | Mechanism | Mortality Benefit | Timing | |---|---|---|---| | ACE-I / ARB | Blocks angiotensin II | ↓ 20–30% | First-line | | Beta-blocker | Blocks catecholamines | ↓ 30–35% | First-line | | Aldosterone antagonist | Blocks aldosterone | ↓ 25–30% | Third-line (after ACE-I + BB) | | ARNI (sacubitril/valsartan) | Neprilysin inhibitor + ARB | ↓ 20% | Replaces ACE-I/ARB | **Clinical Pearl:** Spironolactone is preferred over eplerenone in most settings due to lower cost, though eplerenone is used if gynecomastia develops (spironolactone is a non-selective aldosterone antagonist with anti-androgenic effects). **Warning:** Monitor serum potassium and creatinine closely; contraindicated if K^+^ > 5.5 mEq/L or eGFR < 30 mL/min/1.73m². ## Why Spironolactone is Superior to Other Options - **vs. Amlodipine:** Calcium channel blockers have no mortality benefit in systolic HF and may worsen outcomes in some phenotypes. They are used only for hypertension or angina coexisting with HF. - **vs. Hydralazine-isosorbide dinitrate:** This combination is reserved for patients who cannot tolerate ACE-I/ARB (e.g., renal artery stenosis, severe hyperkalemia) or as adjunctive therapy in African Americans (per BIDIL trial). - **vs. Digoxin:** Digoxin reduces hospitalizations but does NOT reduce mortality. It is now reserved for HF with concurrent atrial fibrillation requiring rate control. [cite:Harrison 21e Ch 272]